Senti Biosciences Receives FDA Orphan Drug Designation

Senti Biosciences ( (SNTI) ) has provided an update.

On June 18, 2025, Senti Biosciences announced that the FDA granted Orphan Drug Designation to SENTI-202, a first-in-class off-the-shelf cell therapy for treating relapsed/refractory hematologic malignancies, including Acute Myeloid Leukemia (AML). This designation is a significant milestone for Senti Bio, as it validates their novel approach to treating AML and highlights the urgent need for new treatment options in this area, with SENTI-202 currently undergoing Phase 1 clinical trials.

The most recent analyst rating on (SNTI) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Senti Biosciences stock, see the SNTI Stock Forecast page.

Spark’s Take on SNTI Stock

According to Spark, TipRanks’ AI Analyst, SNTI is a Neutral.

Senti Biosciences is currently facing significant financial challenges, with ongoing losses and high leverage being the most critical issues. While technical analysis suggests some positive momentum, the overall valuation is weak due to negative earnings. However, recent corporate events, such as promising trial data and strategic leadership changes, provide a positive outlook, offering potential upside if financial stability can be improved.

To see Spark’s full report on SNTI stock, click here.

More about Senti Biosciences

Senti Biosciences is a biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform. The company aims to create medicines with enhanced precision and control, targeting both liquid and solid tumor indications, and has demonstrated preclinical success in using Gene Circuits in NK and T cells.

Average Trading Volume: 114,307

Technical Sentiment Signal: Sell

Current Market Cap: $74.59M

Find detailed analytics on SNTI stock on TipRanks’ Stock Analysis page.